Literature DB >> 11981807

Human natural killer cells: their origin, receptors and function.

Lorenzo Moretta1, Cristina Bottino, Daniela Pende, Maria Cristina Mingari, Roberto Biassoni, Alessandro Moretta.   

Abstract

The term of "natural killer" (NK) cells was originally assigned on a merely functional basis to lymphoid cells capable of lysing certain tumors in the absence of prior stimulation. However, both their origin and the molecular mechanism(s) involved in their function remained a mystery for many years 1. Regarding their origin, clear evidence has now been provided both in mouse and in man that NK and T cells may derive from a common precursor 2-5. Thus, mature NK cells can be obtained in vitro from CD34(+) cells isolated from umbilical cord blood, bone marrow (BM) and even human thymus 6 when cultured in the presence of appropriate feeder cells or IL-15. The molecular mechanism allowing NK cells to discriminate between normal and tumor cells, predicted by the "missing self hypothesis" 7, has been clarified only in recent years. Thus, NK cells recognize MHC class I molecules through surface receptors delivering signals that inhibit, rather than activate, NK cells. As a consequence, NK cells lyse target cells that have lost (or express insufficient amounts of) MHC class I molecules, as frequently occurs in tumors and in cells infected by certain viruses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11981807     DOI: 10.1002/1521-4141(200205)32:5<1205::AID-IMMU1205>3.0.CO;2-Y

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  43 in total

1.  Exclusion of lipid rafts and decreased mobility of CD94/NKG2A receptors at the inhibitory NK cell synapse.

Authors:  Tolib B Sanni; Madhan Masilamani; Juraj Kabat; John E Coligan; Francisco Borrego
Journal:  Mol Biol Cell       Date:  2004-05-07       Impact factor: 4.138

2.  IL-10 induces aberrant deletion of dendritic cells by natural killer cells in the context of HIV infection.

Authors:  Galit Alter; Daniel Kavanagh; Suzannah Rihn; Rutger Luteijn; David Brooks; Michael Oldstone; Jan van Lunzen; Marcus Altfeld
Journal:  J Clin Invest       Date:  2010-05-03       Impact factor: 14.808

3.  Chronic fatigue syndrome is associated with diminished intracellular perforin.

Authors:  K J Maher; N G Klimas; M A Fletcher
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

4.  Improving methods of assessing natural killer cell cytotoxicity.

Authors:  Sandra E Sephton; Helena C Kraemer; Eric Neri; Daniel P Stites; Inka Weissbecker; David Spiegel
Journal:  Int J Methods Psychiatr Res       Date:  2006       Impact factor: 4.035

Review 5.  Immune response to stem cells and strategies to induce tolerance.

Authors:  Puspa Batten; Nadia A Rosenthal; Magdi H Yacoub
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2007-08-29       Impact factor: 6.237

Review 6.  Are circadian rhythms the code of hypothalamic-immune communication? Insights from natural killer cells.

Authors:  Alvaro Arjona; Dipak K Sarkar
Journal:  Neurochem Res       Date:  2007-10-27       Impact factor: 3.996

7.  NK cell survival mediated through the regulatory synapse with human DCs requires IL-15Ralpha.

Authors:  Fabienne Brilot; Till Strowig; Susanne M Roberts; Frida Arrey; Christian Münz
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

8.  Multiplicity and plasticity of natural killer cell signaling pathways.

Authors:  Sabrina Chiesa; Michael Mingueneau; Nicolas Fuseri; Bernard Malissen; David H Raulet; Marie Malissen; Eric Vivier; Elena Tomasello
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

Review 9.  The balancing act: inhibitory Ly49 regulate NKG2D-mediated NK cell functions.

Authors:  Subramaniam Malarkannan
Journal:  Semin Immunol       Date:  2006-06       Impact factor: 11.130

10.  IL15 induces a potent antitumor activity in NK cells isolated from malignant pleural effusions and overcomes the inhibitory effect of pleural fluid.

Authors:  D Croxatto; S Martini; L Chiossone; F Scordamaglia; C F Simonassi; L Moretta; M C Mingari; P Vacca
Journal:  Oncoimmunology       Date:  2017-02-17       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.